Beta-defensin 128

Also known as: Beta-defensin 28, Defensin, beta 128, DEFB128, Q7Z7B8

Beta-defensin 128 (DEFB128) is a member of the beta-defensin family, characterized by a conserved six-cysteine motif that forms three disulfide bridges, conferring antimicrobial properties. Its mechanism of action involves disruption of microbial cell membranes through electrostatic interactions with negatively charged phospholipids, leading to membrane permeabilization and cell lysis. This activity is primarily directed against Gram-positive and Gram-negative bacteria, though specific target spectra remain incompletely characterized due to limited experimental data. Current research on DEFB128 is at an early experimental stage, with only two PubMed-indexed studies available. These studies have focused on gene expression profiling and structural predictions, confirming its classification as a beta-defensin based on sequence homology and cysteine spacing. No functional assays or in vivo models have been published to date, and its tissue-specific expression patterns or potential roles in immune modulation have not been established. Clinically, DEFB128 has no validated applications. Its relevance is speculative, potentially contributing to host defense in epithelial barriers, but the lack of functional characterization precludes any therapeutic or diagnostic utility. Further studies are required to elucidate its antimicrobial spectrum, synergy with other defensins, and possible roles in inflammatory or infectious diseases. For research purposes only — not medical advice.

Key data

Mechanism of action

Has antibacterial activity

Research & studies

Frequently asked questions

Related peptides